Emergency Use of Treatment for Uncontrolled Hemorrhage Due to Agents of Military Combat; Correction, 36941-36942 [2018-16331]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 147 / Tuesday, July 31, 2018 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
daltland on DSKBBV9HB2PROD with NOTICES
National Committee on Vital and Health
Statistics: Meeting
Pursuant to the Federal Advisory
Committee Act, the Department of
Health and Human Services (HHS)
announces the following advisory
committee meeting.
Name: National Committee on Vital
and Health Statistics (NCVHS), Full
Committee Meeting.
Date and Times: Thursday, September
13, 2018: 9:00 a.m.–5:00 p.m. (EDT);
Friday, September 14, 2018: 8:30 a.m.–
3:00 p.m. (EDT).
Place: Melrose Georgetown Hotel,
2430 Pennsylvania Avenue NW,
Washington, DC 20037.
Status: Open.
Purpose: At the September 13–14,
2018 meeting, the Committee will hear
presentations, hold discussions on
several health data policy topics and
continue work on projects outlined in
the NCVHS 2018 workplan. Anticipated
action items during this meeting include
an Environmental Scan Report on
Health Terminologies and Vocabularies
(T/V); and a summary report of the
health T/V expert roundtable meeting
held July 17–18, 2018. The NCVHS
Population Health Subcommittee will
hold a session with panelists to provide
input to the Committee regarding
strategies and resources/tools to
increase access to small area data, and
in general, the challenges in making
relevant sub-national level health data
more readily available. Subcommittee
activities for discussion include the
Predictability Roadmap as part of the
Standards Subcommittee’s project to
identify possible approaches to improve
predictability and improvements in the
adoption and processes related to
updating standards and operating rules
for electronic administrative
transactions (e.g., claims, eligibility,
electronic funds transfer). The Privacy,
Confidentiality & Security
Subcommittee will continue its focus on
use cases that highlight the intersection
of the regulated and unregulated
domains for its ‘‘Health Information
Privacy and Security Beyond HIPAA’’
project, and will propose a model that
depicts the opportunities to address
risks to individually identifiable
information through improved
stewardship for consideration by the
full Committee.
The Committee will initiate
discussion regarding plans for the
NCVHS Thirteenth Report to Congress.
The agenda times and topics are subject
to change. There will be a public
VerDate Sep<11>2014
18:30 Jul 30, 2018
Jkt 244001
comment period on both meeting days.
Please refer to the posted agenda for any
updates.
Contact Persons for More Information:
Substantive program information may
be obtained from Rebecca Hines, MHS,
Executive Secretary, NCVHS, National
Center for Health Statistics, Centers for
Disease Control and Prevention, 3311
Toledo Road, Hyattsville, Maryland
20782, telephone (301) 458–4715.
Summaries of meetings and a roster of
Committee members are available on the
home page of the NCVHS website:
www.ncvhs.hhs.gov, where further
information including an agenda and
instructions to access the audio
broadcast of the meetings will be
posted.
Should you require reasonable
accommodation, please contact the CDC
Office of Equal Employment
Opportunity on (770) 488–3210 as soon
as possible.
Dated: July 25, 2018.
Laina Bush,
Deputy Assistant Secretary for Planning and
Evaluation, Office of the Assistant Secretary
for Planning and Evaluation.
[FR Doc. 2018–16361 Filed 7–30–18; 8:45 am]
BILLING CODE 4151–05–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Emergency Use of Treatment for
Uncontrolled Hemorrhage Due to
Agents of Military Combat; Correction
Office of the Secretary,
Department of Health and Human
Services.
ACTION: Notice, correction.
AGENCY:
The Department of Health and
Human Services is correcting a notice
that appeared in the Federal Register on
July 16, 2018. The notice announced the
Secretary’s Declaration Regarding
Emergency Use of Treatment for
Uncontrolled Hemorrhage During an
Emergency Involving Agents of Military
Combat pursuant to section 564 of the
Federal Food, Drug & Cosmetic (FD&C)
Act. On July 9, 2018, the Secretary
declared that circumstances exist
justifying the authorization of
emergency use of freeze dried plasma
(FDP) for the treatment of hemorrhage or
coagulopathy during an emergency
involving agents of military combat
(e.g., firearms, projectiles, and explosive
devices) when plasma is not available
for use or when the use of plasma is not
practical, pursuant to section 564 of the
FD&C Act, subject to the terms of any
authorization issued under that section.
This notice is correcting the July 16,
SUMMARY:
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
36941
2018 notice to correctly state the
Secretary’s declaration.
FOR FURTHER INFORMATION CONTACT:
Robert P. Kadlec, MD, MTM&H, MS,
Assistant Secretary for Preparedness
and Response, Office of the Secretary,
Department of Health and Human
Services, 200 Independence Avenue
SW, Washington, DC 20201, Telephone
(202) 205–2882 (this is not a toll free
number).
In the
Federal Register of July 16, 2018 (83 FR
32884) appearing on page 32884 in FR
Doc. 2018–15152 the following
corrections are made:
1. Title, change the title of the notice
to ‘‘Declaration Regarding Emergency
Use of Treatment for Hemorrhage or
Coagulopathy During an Emergency
Involving Agents of Military Combat.’’
2. Summary section, change the
second paragraph to: ’’ On the basis of
this determination, on July 9, 2018, the
Secretary declared that circumstances
exist justifying the authorization of
emergency use of freeze dried plasma
(FDP) for the treatment of hemorrhage or
coagulopathy during an emergency
involving agents of military combat
(e.g., firearms, projectiles, and explosive
devices) when plasma is not available
for use or when the use of plasma is not
practical, pursuant to section 564 of the
FD&C Act, subject to the terms of any
authorization issued under that
section.’’
3. SUPPLEMENTARY INFORMATION
section, subpart I, Background, second
paragraph second sentence, delete
‘‘French’’ before ‘‘FDP.’’
4. SUPPLEMENTARY INFORMATION
section, subpart III, Determination of the
Secretary of Health and Human
Services, change paragraph 1 to: ‘‘On
July 9, 2018, on the basis of the Deputy
Secretary of Defense’s determination
that there is a military emergency or
significant potential for a military
emergency involving a heightened risk
to U.S. military forces of an attack with
an agent or agents that may cause, or are
otherwise associated with an
imminently life-threatening and specific
risk to those forces, I declared that
circumstances exist justifying the
authorization of emergency use of FDP
for the treatment of hemorrhage or
coagulopathy during an emergency
involving agents of military combat
(e.g., firearms, projectiles, and explosive
devices) when plasma is not available
for use or when the use of plasma is not
practical, pursuant to section 564 of the
FD&C Act, subject to the terms of any
authorization issued under that
section.’’
SUPPLEMENTARY INFORMATION:
E:\FR\FM\31JYN1.SGM
31JYN1
36942
Federal Register / Vol. 83, No. 147 / Tuesday, July 31, 2018 / Notices
Dated: July 25, 2018.
Ann Agnew,
Executive Secretary to the Department, U.S.
Department of Health and Human Services.
[FR Doc. 2018–16331 Filed 7–30–18; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Meeting
daltland on DSKBBV9HB2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council on Aging.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The meeting
will be closed to the public in
accordance with the provisions set forth
in sections 552b(c)(4) and 552b(c)(6),
Title 5 U.S.C., as amended. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: National Advisory
Council on Aging.
Date: September 13–14, 2018.
Closed: September 13, 2018, 3:00 p.m. to
5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, C Wing 6th Floor Conference
Room 10, 9000 Rockville Pike, Bethesda, MD
20892.
Open: September 14, 2018, 8:00 a.m. to
12:45 p.m.
Agenda: Call to order and report from the
Director; Discussion of future meeting dates;
Consideration of minutes of last meeting;
Reports from Task Force on Minority Aging
Research, Working Group on Program;
Council Speaker; Program Highlights.
Place: National Institutes of Health,
Building 31, C Wing 6th Floor Conference
Room 10, 9000 Rockville Pike, Bethesda, MD
20892.
Contact Person: Robin Barr, Director,
National Institute on Aging, Office of
Extramural Activities, Gateway Building,
7201 Wisconsin Avenue, Bethesda, MD
20814, (301) 496–9322, barrr@nia.nih.gov.
VerDate Sep<11>2014
18:30 Jul 30, 2018
Jkt 244001
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit. Information is also available on the
Institute’s/Center’s home
page:www.nia.nih.gov/about/naca, where an
agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: July 25, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–16294 Filed 7–30–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group Acquired Immunodeficiency
Syndrome Research Review Committee.
Date: August 30–31, 2018.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: San Diego Marriott Mission Valley,
8757 Rio Diego Drive, San Diego, CA 92108.
Contact Person: Robert C. Unfer, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3F40A, National Institutes of Health,
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
NIAID, 5601 Fishers Lane, MSC 9834,
Bethesda, MD 20892–9834, (240) 669–5035,
robert.unfer@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: July 25, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–16296 Filed 7–30–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Quantitative Imaging Tools and Methods for
Cancer Therapy Response Assessment (UG3/
UH3 & U01).
Date: September 7, 2018.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W640, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Saejeong J. Kim, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W640, Bethesda, MD
20892–9750, 240–276–5179, saejeong.kim@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Program Project II.
Date: September 20–21, 2018.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
North Bethesda, MD 20852.
Contact Person: Anita T. Tandle, Ph.D.,
Scientific Review Officer, Research Program
E:\FR\FM\31JYN1.SGM
31JYN1
]]>Agencies
[Federal Register Volume 83, Number 147 (Tuesday, July 31, 2018)]
[Notices]
[Pages 36941-36942]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-16331]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Emergency Use of Treatment for Uncontrolled Hemorrhage Due to
Agents of Military Combat; Correction
AGENCY: Office of the Secretary, Department of Health and Human
Services.
ACTION: Notice, correction.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services is correcting a
notice that appeared in the Federal Register on July 16, 2018. The
notice announced the Secretary's Declaration Regarding Emergency Use of
Treatment for Uncontrolled Hemorrhage During an Emergency Involving
Agents of Military Combat pursuant to section 564 of the Federal Food,
Drug & Cosmetic (FD&C) Act. On July 9, 2018, the Secretary declared
that circumstances exist justifying the authorization of emergency use
of freeze dried plasma (FDP) for the treatment of hemorrhage or
coagulopathy during an emergency involving agents of military combat
(e.g., firearms, projectiles, and explosive devices) when plasma is not
available for use or when the use of plasma is not practical, pursuant
to section 564 of the FD&C Act, subject to the terms of any
authorization issued under that section. This notice is correcting the
July 16, 2018 notice to correctly state the Secretary's declaration.
FOR FURTHER INFORMATION CONTACT: Robert P. Kadlec, MD, MTM&H, MS,
Assistant Secretary for Preparedness and Response, Office of the
Secretary, Department of Health and Human Services, 200 Independence
Avenue SW, Washington, DC 20201, Telephone (202) 205-2882 (this is not
a toll free number).
SUPPLEMENTARY INFORMATION: In the Federal Register of July 16, 2018 (83
FR 32884) appearing on page 32884 in FR Doc. 2018-15152 the following
corrections are made:
1. Title, change the title of the notice to ``Declaration Regarding
Emergency Use of Treatment for Hemorrhage or Coagulopathy During an
Emergency Involving Agents of Military Combat.''
2. Summary section, change the second paragraph to: '' On the basis
of this determination, on July 9, 2018, the Secretary declared that
circumstances exist justifying the authorization of emergency use of
freeze dried plasma (FDP) for the treatment of hemorrhage or
coagulopathy during an emergency involving agents of military combat
(e.g., firearms, projectiles, and explosive devices) when plasma is not
available for use or when the use of plasma is not practical, pursuant
to section 564 of the FD&C Act, subject to the terms of any
authorization issued under that section.''
3. Supplementary Information section, subpart I, Background, second
paragraph second sentence, delete ``French'' before ``FDP.''
4. Supplementary Information section, subpart III, Determination of
the Secretary of Health and Human Services, change paragraph 1 to: ``On
July 9, 2018, on the basis of the Deputy Secretary of Defense's
determination that there is a military emergency or significant
potential for a military emergency involving a heightened risk to U.S.
military forces of an attack with an agent or agents that may cause, or
are otherwise associated with an imminently life-threatening and
specific risk to those forces, I declared that circumstances exist
justifying the authorization of emergency use of FDP for the treatment
of hemorrhage or coagulopathy during an emergency involving agents of
military combat (e.g., firearms, projectiles, and explosive devices)
when plasma is not available for use or when the use of plasma is not
practical, pursuant to section 564 of the FD&C Act, subject to the
terms of any authorization issued under that section.''
[[Page 36942]]
Dated: July 25, 2018.
Ann Agnew,
Executive Secretary to the Department, U.S. Department of Health and
Human Services.
[FR Doc. 2018-16331 Filed 7-30-18; 8:45 am]
BILLING CODE P
